Is KalVista Pharmaceuticals, Inc. (KALV) Halal?
Shariah Screening — 5 Standards
Based on financial data from April 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.8% / 30% | 26.9% / 30% | 1.8% / 30% | N/A | ✓ HALAL |
| DJIM | 0.8% / 33% | 26.9% / 33% | 1.8% / 33% | N/A | ✓ HALAL |
| MSCI | 2.5% / 33% | 88.0% / 33% | 6.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.8% / 33% | 26.9% / 33% | 1.8% / 33% | N/A | ✓ HALAL |
| FTSE | 2.5% / 33% | 88.0% / 33% | 6.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 25.7% | |
| Operating Margin | -21.2% | |
| Net Margin | -223.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$153M |
| Free Cash Flow | -$154M |
| Total Debt | $6M |
| Current Ratio | 5.6 |
| Total Assets | $251M |
Price & Trading
| Last Close | $18.95 |
| 50-Day MA | $16.05 |
| 200-Day MA | $14.18 |
| Avg Volume | 982K |
| Beta | -0.3 |
|
52-Week Range
$9.23
| |
About KalVista Pharmaceuticals, Inc. (KALV)
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE). The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation in adolescent and adult patients. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is KalVista Pharmaceuticals, Inc. (KALV) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), KalVista Pharmaceuticals, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is KalVista Pharmaceuticals, Inc.'s debt ratio?
KalVista Pharmaceuticals, Inc.'s debt ratio is 0.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 2.5%.
What are KalVista Pharmaceuticals, Inc.'s key financial metrics?
KalVista Pharmaceuticals, Inc. has a market capitalization of $990M. The company maintains a gross margin of 25.7% and a net margin of -223.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.